New York Times (NYT) filing to sell 5,000 Class A shares on NYSE
Rhea-AI Filing Summary
The New York Times Company filed a Form 144 notifying a proposed sale of 5,000 Class A shares through Fidelity Brokerage, with an aggregate market value of $290,200.50 and an approximate sale date of 08/12/2025 on the NYSE. The 5,000 shares represent roughly 0.0031% of the 162,038,098 shares outstanding, implying an average price of about $58.04 per share.
The filing shows the securities were acquired via restricted stock vesting on 02/21/2025 (687 shares), 02/22/2025 (362), 02/26/2025 (3,560) and 08/10/2025 (391), with the nature of payment listed as compensation. The notice also records a prior sale of 2,500 shares on 05/30/2025 for gross proceeds of $142,065.00. The filer represents no undisclosed material adverse information is known.
Positive
- Sale size is small relative to the company's outstanding shares (~0.0031%), limiting potential market impact
- Securities were acquired via restricted stock vesting with payment listed as compensation, a routine insider compensation event
Negative
- None.
Insights
TL;DR Routine insider filing: small proposed sale tied to recent RSU vesting; immaterial to cap structure.
The Form 144 documents a proposed sale of 5,000 Class A shares with an aggregate value of $290,200.50, representing ~0.0031% of shares outstanding. The shares were obtained through restricted stock vesting and are being routed through a broker on the NYSE. From a market-impact perspective, the size is negligible relative to the company’s outstanding stock, and prior activity includes a 2,500-share sale on 05/30/2025 for $142,065.00. This appears to be a routine disclosure of insider liquidity following compensation-related vesting.
TL;DR Disclosure aligns with Rule 144 requirements; filing confirms shares originated from compensation vesting and includes required seller representations.
The notice identifies the nature of acquisition as restricted stock vesting across multiple dates and specifies compensation as the payment source, which supports compliance with disclosure norms for Rule 144 sales. The filing includes the standard representation that the selling party is not aware of undisclosed material adverse information. Given the small proportion of outstanding shares represented, this filing is procedural rather than governance-critical.